Immunotherapy has transformed the treatment landscape for cancer, leading to durable remissions in patients with previously refractory disease. The promise of these treatments is limited by inflammatory toxicities that can target any system in the body. Gastrointestinal toxicities, in particular colitis and enterocolitis, are the most common severe toxicities induced by cancer immunotherapy and are a major reason for treatment discontinuation. In this session we will discuss the causes of these toxicities, the optimal workup and available treatment modalities. This knowledge is essential for enabling patients to derive the full benefit from cancer immunotherapy.
Faculty:
Michael Dougan, MD, PhD
Assistant Professor
Massachusetts General Hospital and Harvard Medical School
Joanna Peloquin Melia, MD
Assistant Professor, Division of Gastroenterology and Hepatology
Johns Hopkins
Shrinivas Bishu, MD
Assistant Professor
University of Michigan
Learning Objections:
- understand the presentation and basic mechanisms of GI toxicities from cancer immunotherapy
- understand the differential diagnosis and diagnostic workup for patients presenting with suspected enterocolitis from cancer immunotherapy
- understand treatment options for patients with confirmed enterocolitis from cancer immunotherapy
Pricing
| Member | Nonmember |
|---|---|
| $Free | $Free |
Original release date: Jan. 31, 2023
Expiration date: Jan 31, 2025